Clinical Trial

Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 19, 2026 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective clinical study aims to evaluate and observe the efficacy and safety of Serplulimab Monotherapy in Elderly Patients with NSCLC and PD-L1 TPS ≥ 50% using a multicenter, single-arm, phase II design. The study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 60 patients. The study commenced in May 2026, and recruitment is expected to conclude around May 2026, with the trial anticipated to end by May 2027. Assuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug reactions, or investigator-assessed unsuitability for further participation, each participant's estimated duration of study treatment will continue until radiographically confirmed tumor progression.
Trial Details
NCT Number NCT07596121
Lead Sponsor Tang-Du Hospital
Conditions NSCLC (Non-small Cell Lung Cancer)
Enrollment 60 participants
Start Date 2026-05-13
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-19